ArticleAmerican journal of hematology2017

Frequency, risk factors, and outcomes of central nervous system relapse in lymphoma patients treated with dose-adjusted EPOCH plus rituximab.

Mary-Kate Malecek et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.